To determine the minimal clinically important difference (MCID), patient-reported outcome measures (PROMs) are presented that cover the dimensions 1. subjective hearing ability, 2. hearing-specific quality of life, and 3. generic quality of life, which are largely mentioned in corresponding guidelines and recommendations for device provision and aural rehabilitation in Germany....
✦ The floor
Discussion
Signed responses from readers of the wire.
CI programs should carefully interpret patient-reported outcome measures using established minimal clinically important difference thresholds to avoid overstating treatment benefits; methodological rigor in PROM analysis should be adopted now.
Properly applying MCID thresholds in cochlear implant PROMs is essential for accurately judging whether patients experience real-world benefit, informing both clinical decisions and health policy.
- 01Examines methodological use of MCID in patient-reported outcomes (PROMs) for cochlear implant provision.
- 02Covers both subjective hearing ability and hearing-specific quality of life measures.
- 03Published in HNO (German-language ENT journal) (2026).
- 04Relevant to how CI programs report and interpret treatment effectiveness.
- 05Has implications for health technology assessment and reimbursement decisions.
The minimal clinically important difference (MCID) has significant methodological implications for interpreting PROMs in cochlear implant provision.
opinionpartially supported- PMID
- 42841941
- DOI
- 10.1007/s00106-026-01815-4.
- Journal
- HNO
- Publication type
- review
- Evidence level
- 5
- Population
- Cochlear implant recipients assessed via patient-reported outcome measures
- Intervention
- Application of minimal clinically important difference (MCID) to PROMs in CI provision
Primary outcomes
Methodological implications of MCID for subjective hearing ability PROMs; Methodological implications of MCID for hearing-specific quality of life PROMs